<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429182</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0280</org_study_id>
    <nct_id>NCT00429182</nct_id>
  </id_info>
  <brief_title>Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn the relationship of high-dose
      chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast
      cancer. The study also will investigate the role of CTCs in breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may
      slow or stop their growth and spread throughout the body. This may cause the cancer cells to
      die. Carboplatin and thiotepa are designed to interfere with the growth of cancer cells by
      stopping cell division, which may cause the cells to die. Mesna is designed to prevent
      toxicities from cyclophosphamide. Granulocyte colony-stimulating factor (G-CSF or GCSF) is
      designed to help your white blood count recover after transplant.

      If you are found to be eligible to take part in this study, you will be given G-CSF twice a
      day through a needle under the skin (subcutaneous injection), on Days 1-5. On Day 5, stem
      cell collection will begin. You will have a catheter placed into a vein in your chest. A
      central venous catheter is a sterile flexible tube that will be placed into a large vein
      while you are under local anesthesia. Your physician will explain this procedure to you in
      more detail, and you will be required to sign a separate consent form for this procedure.

      If further shrinkage of tumor is needed, the doctor may use chemotherapy combined with G-CSF
      described above. Your doctor will explain this procedure to you in more detail, and you will
      be asked to sign a separate consent form for this procedure.

      Blood will be removed from your body through the catheter and passed through a machine that
      separates the stem cells from the other cells. The stem cells will be frozen for storage, and
      the blood will be returned to your body. This 3-hour process is called apheresis. The process
      will be done once a day for 1-6 days until enough stem cells are collected. Blood ( about 4
      teaspoons) will be collected at the first Apheresis to have as a comparison sample to check
      for any breast cancer leftover in the blood.

      The collected blood cells will go through a filter to select out the blood stem cells and the
      CTCs will be left behind.

      Blood (about 2 tablespoons) will be drawn daily during peripheral blood stem cell collection.

      On Days 6, 5, 4, and 3 before the transplant, you will receive cyclophosphamide, mesna,
      thiotepa, and carboplatin through a needle in your vein. Blood (about 2 teaspoons) will be
      drawn for routine tests.

      On Day 0, your stem cells will be transplanted. Stem cells will go through a device to remove
      the breast cancer cells. If the bone marrow is collected because there was not enough stem
      cells, researchers will not treat the bone marrow to remove breast cancer cells. Collected
      breast cancer cells will be studied to understand the biological role of these cancer cells.

      After the transplant, G-CSF will be given through a needle under your skin until the white
      blood cell count is normal for 3 days in a row.

      Blood (about 2 tablespoons) will be drawn daily after the transplant while you are still in
      the hospital. You are expected to remain in the hospital for 3 weeks. Once you are released
      from the hospital, you will have blood (about 2 tablespoons) drawn for routine tests every
      week until your cell counts recover.

      Five (5) weeks after your transplant, if your doctor thinks it is needed, you will have
      radiation therapy, hormonal therapy, or receive trastuzumab.

      At Months 1, 3, 6, 9, 12, 16, 20, and 24 after the transplant, your complete medical history
      will be recorded, and you will have a physical exam. You will have a chest X-ray and bone
      scan. If your doctor thinks it is needed, you will have an x-ray of hot spots which are areas
      that show positive on the bone scan. If your doctor thinks it is needed, you may have a CT
      scan of the head, a mammogram, or a breast ultrasound performed. At Months 1 and 3 after the
      transplant, you will have a PET/CT scan. At Months 6, 9, 12, 16, 20, and 24 after the
      transplant, you will have a CT scan of the chest and abdomen then as needed to check the
      status of the disease. Blood (about 2 teaspoons) will be drawn to measure cancer markers and
      CTCs.

      While on study you must notify the doctor of any new drugs you are taking.

      This is an investigational study. The transplant is not FDA approved. The drugs G-CSF,
      cyclophosphamide, carboplatin, and thiotepa are all approved by the FDA and commercially
      available. The CliniMACS device is not commercially available or FDA approved. The CliniMACS
      device is being used in research only and will be provided free of charge. Up to 70 patients
      will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products</measure>
    <time_frame>Baseline to 1 month post AHST</time_frame>
    <description>Number of circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both as longitudinal values and compared to the baseline number of CTCs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival (PFS)</measure>
    <time_frame>Overall study (baseline to disease progression)</time_frame>
    <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression. PFS time measured in months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastatic Breast Carcinoma</condition>
  <condition>Invasive Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>High-dose chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin + Cyclophosphamide + Thiotepa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.</description>
    <arm_group_label>High-dose chemotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
    <arm_group_label>High-dose chemotherapy</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
    <arm_group_label>High-dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Stem Cell Transplant on Day 0.</description>
    <arm_group_label>High-dose chemotherapy</arm_group_label>
    <other_name>SCT</other_name>
    <other_name>Autologous hematopoietic stem cell transplantation</other_name>
    <other_name>AHST</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 55 years old

          2. Metastatic breast carcinoma.

          3. Histological confirmation of invasive breast carcinoma

          4. Complete or partial response to pre-transplant standard-dose chemotherapy, or hormonal
             therapy. For bone disease, stable disease (SD) is allowed.

          5. Patient must have tumor assessed for estrogen-receptor (ER) and progesterone-receptor
             (PR).

          6. Persistent detectable or non-detectable CTCs by Veridex Technology after completion of
             standard therapy.

          7. Zubrod performance status 0 or 1.

          8. Patients must have adequate hematological parameters (White Blood Count/WBC &gt;=
             3,000/mm3; platelet count &gt;= 100,000/mm3)

          9. Adequate renal function (serum creatinine &lt;= 1.5mg/dl)

         10. Adequate liver function (total bilirubin, serum glutamate pyruvate transaminase (SGPT)
             &lt;= 2 times normal).

         11. Adequate cardiac function (Left ventricular ejection fraction (LVEF)&gt;= 50%).

         12. Adequate pulmonary function (Carbon Monoxide Diffusing Capacity (DLCO)&gt;= 50% of
             predicted value).

         13. Females of childbearing (women who are post-menopausal &lt; 1 year, not surgically
             sterilized, or not abstinent) potential must use adequate contraception.

         14. Patients must sign an informed consent.

        Exclusion Criteria:

          1. Prior HDCT with Autologous hematopoietic stem cell transplantation (AHST) in adjuvant
             setting.

          2. History or presence of brain/leptomeningeal metastasis.

          3. History of other malignancies except cured non-melanoma skin cancer or cured cervical
             carcinoma in situ.

          4. Presence of other severe medical illnesses or conditions. Severe heart disease,
             (myocardial ischemia, myocardial infarction, etc.) Pulmonary disease (COPD,
             asthma,etc). Renal failure and hepatic failure.

          5. Clinically significant active infections (patient requiring IV antibiotics,
             uncontrolled infections, or hospitalized due to infections).

          6. HIV infection.

          7. Pregnant or lactating women.

          8. Medical, social or psychologic factors which would prevent the patient from receiving
             or cooperating with the full course of therapy or understanding the informed consent
             procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoto Ueno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <results_first_submitted>February 28, 2013</results_first_submitted>
  <results_first_submitted_qc>February 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2013</results_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>breast carcinoma</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paraplatin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Neosar</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Thiotepa</keyword>
  <keyword>Purged Autologous Stem Cells</keyword>
  <keyword>Circulating Tumor Cells</keyword>
  <keyword>CTCs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: February 27, 2007 to July 25, 2011. All Recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>High-dose Chemotherapy</title>
          <description>Carboplatin + Cyclophosphamide + Thiotepa
Carboplatin : Target area under the curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
Stem Cell Transplant : Stem Cell Transplant on Day 0.
Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not evaluable, Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not eligible</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-dose Chemotherapy</title>
          <description>Carboplatin + Cyclophosphamide + Thiotepa
Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
Stem Cell Transplant : Stem Cell Transplant on Day 0.
Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="29" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products</title>
        <description>Number of circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both as longitudinal values and compared to the baseline number of CTCs.</description>
        <time_frame>Baseline to 1 month post AHST</time_frame>
        <population>Twenty-one participants provided blood samples for the enumeration of CTCs, before apheresis (baseline) and at one month after AHST.</population>
        <group_list>
          <group group_id="O1">
            <title>High-dose Chemotherapy</title>
            <description>Carboplatin + Cyclophosphamide + Thiotepa
Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
Stem Cell Transplant : Stem Cell Transplant on Day 0.
Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products</title>
          <description>Number of circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both as longitudinal values and compared to the baseline number of CTCs.</description>
          <population>Twenty-one participants provided blood samples for the enumeration of CTCs, before apheresis (baseline) and at one month after AHST.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression Free Survival (PFS)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression. PFS time measured in months.</description>
        <time_frame>Overall study (baseline to disease progression)</time_frame>
        <population>Six participants were not evaluable for outcome assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>High-dose Chemotherapy</title>
            <description>Carboplatin + Cyclophosphamide + Thiotepa
Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
Stem Cell Transplant : Stem Cell Transplant on Day 0.
Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression Free Survival (PFS)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression. PFS time measured in months.</description>
          <population>Six participants were not evaluable for outcome assessment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="1" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High-dose Chemotherapy</title>
          <description>Carboplatin + Cyclophosphamide + Thiotepa
Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
Stem Cell Transplant : Stem Cell Transplant on Day 0.
Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naoto Ueno, MD / Professor</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

